SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Top Breakfast Food: What's Your Morning Enjoyment? - 2Manual for Tracking down One of a kind Store Inns
- 3New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- 4Overlooked infertility care should be part of national health services, says WHO
- 5British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- Top 15 Style Creators Changing the Business
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Mississippi Insight for Jan. 11, 2026
- Investigate the Excellence of Professional flowerbeds: A Virtual Local escort
